Dr Giuseppe Curigliano speaks to ecancer at ASCO 2024 about results from DESTINY-Breast06 - a study evaluating trastuzumab deruxtecan versus physician’s choice of chemotherapy in patients with hormone receptor-positive (HR positive), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer with prior endocrine therapy.
The 866 participants were randomly assigned to receive either trastuzumab deruxtecan or a chemotherapy of their doctor’s choice.
For those with HER2-low cancer, the median progression-free survival was 13.2 months for those who received trastuzumab deruxtecan versus 8.1 months for those who received chemotherapy.